Ryan Allway March 30th, 2021 Psychedelics Toronto, Ontario–(Newsfile Corp. – March 30, 2021) – Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) (FSE: 9DF) (“Mindset” or the “Company“), a drug discovery and development company focused on developing next generation psilocybin and N,N-Dimethyltryptamine (DMT) inspired medicines and related technologies, is pleased to announce that it... Read more
Ryan Allway March 29th, 2021 Psychedelics BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU ) is pleased to announce that it has been added to the Horizons Psychedelic Stock Index ETF ( PSYK : NEO), the world’s first ETF offering direct... Read more
Ryan Allway March 26th, 2021 German, Psychedelics Alexander Flemmings zufällige Entdeckung von Penicillin steht in krassem Gegensatz zu den typischen Prozessen und Zeitplänen, die mit der Entdeckung von Arzneimitteln verbunden sind. Im Gegenteil, die meisten Medikamente werden nicht versehentlich entdeckt, sondern über lange Zeiträume von 5 bis 15 Jahren... Read more
Liam Harrison March 25th, 2021 Psychedelics, Top News Alexander Flemming’s accidental discovery of penicillin exists in stark contrast to the typical processes and timelines associated with drug discovery. Most drugs, on the contrary, are not accidentally discovered and are developed over long timelines ranging from 5 to 15 years,... Read more
Ryan Allway March 20th, 2021 Psychedelics Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (“Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it has filed a pre-IND (Investigational New Drug) meeting request with the U.S. FDA for its investigation of AP-188 (“N,N-Dimethyltryptamine or DMT”),... Read more
Ryan Allway March 19th, 2021 Psychedelics, Top News TORONTO, March 19, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce... Read more
Ryan Allway March 18th, 2021 Psychedelics KELOWNA, British Columbia, March 18, 2021 (GLOBE NEWSWIRE) — Allied Corp. (“Allied”) (OTCQB: ALID), an international medical cannabis company focused on creating and providing targeted psilocybin and cannabinoid health solutions to address today’s medical issues, is pleased to announce that it has submitted a provisional... Read more
TORONTO, ON / ACCESSWIRE / March 18, 2021 / Novamind Inc. (CSE: NM, OTC: NVMDF, FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that its wholly-owned subsidiary, Cedar Clinical Research (“CCR”) has been selected as a key research site for a... Read more
La Jolla, California–(Newsfile Corp. – March 18, 2021) – Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today that it has submitted a provisional patent (US 63/161,070) to improve how psychedelics are administered across a broad range of... Read more
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more